

Figure S1 Flowchart of inclusion criteria for patients. MIE, minimally invasive esophagectomy.

Factors	Univariate analysis			Multivariate analysis		
Factors	HR	95% CI	P value	HR	95% CI	P value
Period						
2011–2012	Ref.					
2013–2014	1.034	0.737-1.452	0.845			
2015–2017	0.832	0.589-1.175	0.297			
Age						
≤65	Ref.					
>65	1.435	1.048-1.964	0.024			
Sex						
Female	Ref.					
Male	0.815	0.588-1.128	0.218			
ASA score						
I–II	Ref.					
III–IV	1.493	1.033–2.156	0.033			
BMI (kg/m²)						
≤18.5	Ref.					
18.5–25	1.383	0.860-2.226	0.181			
≥25	1.659	0.951-2.893	0.075			
Tumor location						
Proximal	Ref.					
Mid	1.426	0.838-2.426	0.191			
Distal	1.416	0.801-2.501	0.231			
Histologic grade						
Gx/G1	Ref.					
G2	1.086	0.820-1.437	0.566			
G3	1.189	0.733-1.929	0.484			
TNM stage						
I	Ref.			Ref.		
II	2.232	1.389–3.587	0.001	2.09	1.299–3.363	0.002
Ш	4.37	2.839-6.728		4.253	2.761-6.552	<0.001
IVA	8.642	4.707-15.866		8.77	4.766–16.137	<0.001
Surgical procedure						
McKeown	Ref.					
Ivor Lewis	0.825	0.543-1.252	0.366			
Lymphadenectomy						
Two-field	Ref.					
Three-field	0.823	0.536-1.261	0.371			
Blood loss (mL)						
≤100	Ref.			Ref.		
100-200	1.18	0.883-1.578	0.262	1.156	-0.863-1.547	0.331
≥200	2.443	1.612-3.702	< 0.001	2.382	1.559-3.637	<0.001
Smoking status						
Never	Ref.					
Current/former	0.93	0.711-1.215	0.593			
Adjuvant chemotherapy	0.30	0.711 1.210	0.000			
No	Ref.					
Yes	нет. 1.288	0.984–1.686	0.066			
TO	1.200	0.304-1.000	0.000			
	Def			Def		
No Yes	Ref. 0.674		0.004	Ref.		

DFS, disease-free survival; ASA, American Society of Anesthesiology; BMI, body mass index; TO, textbook outcome; HR, hazard ratio; CI, confidence interval.

Factors	Univariate analysis			Multivariate analysis		
	HR	95% CI	P value	HR	95% CI	P value
Period						
2011–2012	Ref.					
2013–2014	0.907	0.616-1.336	0.621			
2015–2017	0.594	0.398-0.886	0.011			
Age						
≤65	Ref.					
>65	1.323	0.903-1.938	0.151			
Sex						
Female	Ref.					
Male	0.908	0.622-1.324	0.615			
ASA score						
1–11	Ref.					
III–IV	1.503	0.977-2.310	0.063			
BMI (kg/m²)						
≤18.5	Ref.	_				
18.5–25	1.503	0.829-2.726	0.18			
≥25	2.01	1.022-3.953	0.043			
Tumor location	2.01	1.022-0.300	0.040			
Proximal	Ref.					
Mid	1.315	0 705 0 450	0.39			
		0.705-2.452				
Distal	1.465	0.755–2.841	0.259			
Histologic grade	Def					
Gx/G1	Ref.	0.007.4.040	0.051			
G2	1.175	0.837-1.649	0.351			
G3	1.448	0.834–2.514	0.189			
TNM stage						
1	Ref.			Ref.		
II	1.251	1.251-4.084	0.007	2.347	1.256–4.386	
III	4.874	2.858-8.313	<0.001	5.182	2.896-9.273	<0.001
IVA	9.922	4.833–20.369	<0.001	11.166	5.249–23.752	<0.001
Surgical procedure						
McKeown	Ref.					
Ivor Lewis	0.824	0.497–1.364	0.451			
Lymphadenectomy						
Two-field	Ref.					
Three-field	1.157	0.729–1.837	0.536			
Blood loss (mL)						
≤100	Ref.			Ref.		
100–200	1.287	0.911–1.817	0.152	1.197	0.842-1.702	0.317
≥200	2.518	1.537–4.125	<0.001	2.065	1.235–3.451	0.006
Smoking status						
Never	Ref.					
Current/former	0.89	0.647-1.224	0.474			
Adjuvant chemotherapy						
No	Ref.					
Yes	1.482	1.070-2.051	0.018			
ТО						
No	Ref.			Ref.		
Yes	0.633	0.459-0.872	0.005	0.71	0.512-0.985	0.04

RFS, Recurrence-free survival; ASA, American Society of Anesthesiology; BMI, body mass index; TO, textbook outcome; HR, hazard ratio; CI, confidence interval.




Figure S2 Nomogram prediction for the possibility of achieving TO. TO, textbook outcome.